Clavis Pharma completes patient recruitment in Phase III study with elacytarabine in patients with acute myeloid leukaemia
Clavis Pharma ASA announced that is has reached the enrolment target for its Phase III CLAVELA study investigating elacytarabine in patients with relapsed or refractory acute myeloid leukaemia (AML). Elacytarabine is a novel, patented lipid-conjugated form of the anti-cancer drug cytarabine, which is routinely used in the treatment of AML.
The CLAVELA study is a 380-patient Phase III open-label randomised, controlled trial comparing elacytarabine with the investigator’s choice of treatment in patients with relapsed or refractory AML. The study is being conducted at 76 clinical sites in the USA, Canada, Europe and Australia. The primary endpoint of the study is overall survival (OS) and the objective is to demonstrate superiority of elacytarabine over current therapies. Patients have been randomised to each arm of the study and the difference in OS and other parameters, including response rates, duration of response, and safety profile of elacytarabine, will be measured. Top-line data are expected to be available in Q1 2013.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Feeding RNAs to a molecular shredder
Quality assurance in cells power plants
The LifeGene project provides unique insight into the causes of disease
Government Initiatives to Encourage Adoption of Healthcare IT Solutions in Poland, Finds Frost & Sullivan
VABIOTECH licenses cell-based japanese encephalitis technology from Inviragen

Molecular mechanisms of corona drug candidate Molnupiravir unraveled - Mutations in the genome stop the virus

Quickseal® Protective Silicone Cap 1/4" (6.4mm) | Safety caps | Sartorius

Tracking the Happiness Hormone - Electrochemical serotonin microsensors for stable long-term measurement in real time
Molecule determines friendships
How Noroviruses control their desire for sweets
FORMAC strengthens management with appointment of CSO and COO
